News & Updates
Filter by Specialty:
PLD-apatinib combo show promise for ovarian cancer
A combination regimen comprising apatinib, a small-molecule TKI*, and pegylated liposomal doxorubicin (PLD) led to improved progression-free survival (PFS) in women with platinum-resistant recurrent ovarian cancer (PROC), results of the APPROVE trial suggest.
PLD-apatinib combo show promise for ovarian cancer
03 Oct 2022
Women, diabetics more likely to suffer from delayed gastric emptying after gastrectomy
Among patients who undergo distal gastrectomy for gastric cancer, the risk of developing delayed gastric emptying (DGE) appears to be higher among women and those with diabetes, according to a recent study.
Women, diabetics more likely to suffer from delayed gastric emptying after gastrectomy
03 Oct 2022
Use of RAS inhibitors associated with lower cancer risk in T2D
A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.
Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
28 Sep 2022
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.